Gene Editing, Genetics, Genomics and Regulation

Gene editing: beyond the hype

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”. Zinc fingers.

Gene Editing

Gene Editing Gene Gene Therapy In-Vivo

Delivering on the promise of gene editing

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Gene Editing

Gene Editing Gene In-Vivo Genome

STAT+: At genome-editing summit, experts worry that rule changes on embryo research in China fall short

STAT News

MARCH 6, 2023

LONDON — The first gene-edited children were born in China five years ago , but it’s unlikely to happen again there anytime soon. That was the message Chinese scientists delivered Monday on the opening day of the Third International Summit on Human Genome Editing in London.

Genome

Genome Genomics Gene Editing Genetics

The FDA’s Guidance on Gene Edited Foods + What American Foods are Banned in Other Countries? – Xtalks Food Podcast Ep. 149

XTalks

MARCH 7, 2024

In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. Genome editing stands as a cutting-edge technique that ingeniously introduces new traits into plants.

Gene Editing

Gene Editing Gene Genome Genomics

New research begins to write the rules on CRISPR activation

Drug Discovery World

MARCH 21, 2023

CRISPR activation (CRISPRa) is a type of CRISPR gene editing that is used to overexpress certain genes. Although this technique is broadly used, predicting its efficiency when aimed at certain points in the genome can be challenging, making it hard to reliably overexpress certain genes.

Research

Research Gene Gene Editing Genome

Mapping Networks of Immune Genes Behind Autoimmune Diseases

XTalks

JULY 14, 2022

However, there is limited knowledge about the upstream regulators of most genes. A downstream approach has traditionally been used by scientists to map networks, wherein a gene for a protein is removed one at a time and the impact on the immune cell’s function is observed. All 24 of the regulators affected the levels of IL2RA.

Gene

Gene Regulation Protein Gene Editing

Johns Hopkins Researchers Identify CRISPR Dimmer

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. In bacteria with unaltered tracr-L, levels of CRISPR-related genes were low. The authors suggest natural tracr-L regulates autoimmunity.

Bacteria

Bacteria Gene Editing Research RNA

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

NOVEMBER 27, 2023

In addition, it has stimulated increased collaboration among drug developers, technology providers, supply chain organisations, and regulators. Next-generation engineering tools, such as gene editing have enabled knock-out cell lines with enhanced characteristics.

Production

Production Engineer Gene Editing Gene

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. While type II (Cas9) is mainly used for gene-editing applications, CRISPR detecting tools primarily rely on type V (Cas12) and type VI (Cas13) collateral activity.

DNA

DNA Genome Genomics RNA

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. Epigenetic Editing with CRISPR.

DNA

DNA Gene Gene Silencing Genome

The regulatory round-up: Eight key FDA decisions

Drug Discovery World

APRIL 4, 2023

Read more: FDA Fast Track Designation for retinitis pigmentosa treatment Drug candidate for TUBB4a leukodystrophy, SynaptixBio The FDA has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.

FDA Approval

FDA Approval In-Vivo Gene Editing Drugs

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Infectious disease expert, epidemiologist and director of the Yale Institute for Global Health at Yale University, Saad B.

Life Science

Life Science Vaccination Vaccine Gene

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. Epigenome Editing with CRISPR.

DNA

DNA Gene Gene Silencing Genome

What to expect from drug discovery and development in 2023

Drug Discovery World

JANUARY 26, 2023

These changes will not only benefit the application of AI and ML in biotech, but improve scalability and efficiency in R&D overall.” Genomics According to GlobalData genomics will play a significant role throughout 2023 in terms of how the industry understands, prevents and treats diseases.

Development

Development Drugs Clinical Trials Clinical Trials

New Rare Disease Drugs and Research Advancements

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. These regulations offer benefits such as tax credits, grant funding and extended market exclusivity for approved drugs.

Research

Research Drugs Gene Therapy Clinical Trials

Regulatory Trends in Cell and Gene Therapies

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy

Gene Therapy Gene Production Clinical Trials

Who are the AACR Scientific Achievement Award winners?

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics

Genetics Research Medicine Clinical Research

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Pharma Marketing Network

JANUARY 20, 2021

In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. When the patient is referred, a large historical data set (including biomarker and genetic data) will be available to the provider.

Vaccination

Vaccination Vaccine In-Vivo Genetics

Clinical Research Informer

Gene editing: beyond the hype

Delivering on the promise of gene editing

Trending Sources

STAT+: At genome-editing summit, experts worry that rule changes on embryo research in China fall short

The FDA’s Guidance on Gene Edited Foods + What American Foods are Banned in Other Countries? – Xtalks Food Podcast Ep. 149

New research begins to write the rules on CRISPR activation

Mapping Networks of Immune Genes Behind Autoimmune Diseases

Johns Hopkins Researchers Identify CRISPR Dimmer

Advancements in upstream CLD for enhanced biotherapeutics production

CRISPR breakthroughs: New solutions for common diseases

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

The regulatory round-up: Eight key FDA decisions

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

What to expect from drug discovery and development in 2023

New Rare Disease Drugs and Research Advancements

Regulatory Trends in Cell and Gene Therapies

Who are the AACR Scientific Achievement Award winners?

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Stay Connected